Targeting the embryonic gene Cripto-1 in cancer and beyond

Bibliography

• Bianco C, Rangel MC, Castro NP, Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol 2010;177:532-40
   PubMed Web of Science ®Google Scholar
• de Castro NP, Rangel MC, Nagaoka T, Cripto-1: an embryonic gene that promotes tumorigenesis. Future Oncol 2010;6:1127-42
   PubMed Web of Science ®Google Scholar
• Colas JF, Schoenwolf GC. Subtractive hybridization identifies chick-cripto, a novel EGF-CFC ortholog expressed during gastrulation, neurulation and early cardiogenesis. Gene 2000;255:205-17
   PubMed Web of Science ®Google Scholar
• Minchiotti G, Manco G, Parisi S, Structure-function analysis of the EGF-CFC family member Cripto identifies residues essential for nodal signalling. Development 2001;128:4501-10
   PubMedGoogle Scholar
• Watanabe K, Bianco C, Strizzi L, Growth factor induction of Cripto-1 shedding by GPI-phospholipase D and enhancement of endothelial cell migration. J Biol Chem 2007;282:31643-55
   PubMedGoogle Scholar
• Watanabe K, Hamada S, Bianco C, Requirement of glycosylphosphatidylinositol anchor of Cripto-1 for ‘trans’ activity as a nodal co-receptor. J Biol Chem 2007;289:35772-86
   Google Scholar
• Minchiotti G, Parisi S, Liguori G, Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development. Mech Dev 2000;90:133-42
   PubMedGoogle Scholar
• Schiffer SG, Foley S, Kaffashan A, Fucosylation of Cripto is required for its ability to facilitate nodal signaling. J Biol Chem 2001;276:37769-78
   PubMed Web of Science ®Google Scholar
• Shi S, Ge C, Luo Y, The threonine that carries fucose, but not fucose, is required for Cripto to facilitate nodal signaling. J Biol Chem 2007;282:20133-41
   Google Scholar
• Rabbani SA, Mazar AP, Bernier SM, Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992;267:14151-6
   PubMed Web of Science ®Google Scholar
• Rampal R, Luther KB, Haltiwanger RS. Notch signaling in normal and disease States: possible therapies related to glycosylation. Curr Mol Med 2007;7:427-45
   PubMedGoogle Scholar
• Bianco C, Mysliwiec M, Watanabe K, Activation of a Nodal-independent signaling pathway by Cripto-1 mutants with impaired activation of a Nodal-dependent signaling pathway. FEBS Lett 2008;582:3997-4002
   Google Scholar
• Bianco C, Strizzi L, Mancino M, Regulation of Cripto-1 signaling and biological activity by caveolin-1 in mammary epithelial cells. Am J Pathol 2008;172:345-57
   PubMedGoogle Scholar
• Bianco C, Strizzi L, Normanno N, Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol 2005;67:85-133
   PubMed Web of Science ®Google Scholar
• Strizzi L, Bianco C, Normanno N, Salomon D. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene 2005;24:5731-41
   PubMed Web of Science ®Google Scholar
• Reissmann E, Jornvall H, Blokzijl A, The orphan receptor ALK7 and the activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development. Genes Dev 2001;15:2010-22
   PubMed Web of Science ®Google Scholar
• Gray PC, Harrison CA, Vale W. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci USA 2003;100:5193-8
   PubMed Web of Science ®Google Scholar
• Gray PC, Shani G, Aung K, Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling. Mol Cell Biol 2006;26:9268-78
   PubMed Web of Science ®Google Scholar
• Adkins HB, Bianco C, Schiffer SG, Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 2003;112:575-87
   PubMed Web of Science ®Google Scholar
• Shani G, Fischer WH, Justice NJ, GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth. Mol Cell Biol 2008;28:666-77
   PubMed Web of Science ®Google Scholar
• Bianco C, Strizzi L, Rehman A, A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res 2003;63:1192-7
   PubMed Web of Science ®Google Scholar
• Bianco C, Adkins HB, Wechselberger C, Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol 2002;22:2586-97
   PubMed Web of Science ®Google Scholar
• Watanabe K, Nagaoka T, Lee JM, Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1. J Cell Biol 2009;187:343-53
   PubMed Web of Science ®Google Scholar
• Hamada S, Watanabe K, Hirota M, beta-Catenin/TCF/LEF regulate expression of the short form human Cripto-1. Biochem Biophys Res Commun 2007;355:240-4
   PubMedGoogle Scholar
• Morkel M, Huelsken J, Wakamiya M, Beta-catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development 2003;130:6283-94
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Dono R, Kim N, Expression of Cripto, a novel gene of the epidermal growth factor gene family, leads to in vitro transformation of a normal mouse mammary epithelial cell line. Cancer Res 1991;51:1051-4
   PubMedGoogle Scholar
• Niemeyer CC, Persico MG, Adamson ED. Cripto: roles in mammary cell growth, survival, differentiation and transformation. Cell Death Differ 1998;5:440-9
   PubMedGoogle Scholar
• Brandt R, Normanno N, Gullick WJ, Identification and biological characterization of an epidermal growth factor-related protein: Cripto-1. J Biol Chem 1994;269:17320-8
   PubMed Web of Science ®Google Scholar
• Wechselberger C, Ebert AD, Bianco C, Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. Exp Cell Res 2001;266:95-105
   PubMed Web of Science ®Google Scholar
• Ebert AD, Wechselberger C, Nees M, Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells. Exp Cell Res 2000;257:223-9
   PubMedGoogle Scholar
• Normanno N, De Luca A, Bianco C, Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J Cell Physiol 2004;198:31-9
   PubMed Web of Science ®Google Scholar
• Strizzi L, Bianco C, Normanno N, Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol 2004;201:266-76
   PubMed Web of Science ®Google Scholar
• Bianco C, Strizzi L, Ebert A, Role of human Cripto-1 in tumor angiogenesis. J Natl Cancer Inst 2005;97:132-41
   PubMed Web of Science ®Google Scholar
• Bianco C, Cotten C, Lonardo E, Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. Am J Pathol 2009;175:2146-58
   PubMed Web of Science ®Google Scholar
• Wechselberger C, Strizzi L, Kenney N, Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene 2005;24:4094-105
   PubMed Web of Science ®Google Scholar
• Sun Y, Strizzi L, Raafat A, Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. Am J Pathol 2005;167:585-97
   Google Scholar
• Miyoshi K, Shillingford JM, Le Provost F, Activation of beta -catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci USA 2002;99:219-24
   PubMed Web of Science ®Google Scholar
• Miyoshi K, Rosner A, Nozawa M, Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene 2002;21:5548-56
   PubMedGoogle Scholar
• Kuniyasu H, Yasui W, Akama Y, Expression of Cripto in human gastric carcinomas: an association with tumor stage and prognosis. J Exp Clin Cancer Res 1994;13:151-7
   Google Scholar
• Saeki T, Stromberg K, Qi CF, Differential immunohistochemical detection of amphiregulin and Cripto in human normal colon and colorectal tumors. Cancer Res 1992;52:3467-73
   PubMed Web of Science ®Google Scholar
• Saeki T, Salomon DS, Johnson GR, Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 1995;25:240-9
   PubMed Web of Science ®Google Scholar
• Panico L, D'Antonio A, Salvatore G, Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer 1996;65:51-6
   PubMed Web of Science ®Google Scholar
• Haruma K, Ito M, Kohmoto K, Expression of cell cycle regulators and growth factor/receptor systems in gastric carcinoma in young adults: association with Helicobacter pylori infection. Int J Mol Med 2000;5:185-90
   Google Scholar
• De Angelis E, Grassi M, Gullick WJ, Expression of Cripto and amphiregulin in colon mucosa from high risk colon cancer families. Int J Oncol 1999;14:437-40
   Google Scholar
• Miyoshi N, Ishii H, Mimori K, TDGF1 is a novel predictive marker for metachronous metastasis of colorectal cancer. Int J Oncol 2010;36:563-8
   Google Scholar
• Gong YP, Yarrow PM, Carmalt HL, Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. Eur J Surg Oncol 2007;33:438-43
   Google Scholar
• Bianco C, Strizzi L, Mancino M, Identification of Cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res 2006;12:5158-64
   PubMed Web of Science ®Google Scholar
• Normanno N, Bianco C, Damiano V, Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. Clin Cancer Res 1996;2:601-9
   PubMed Web of Science ®Google Scholar
• Hu XF, Xing PX. Cripto as a target for cancer immunotherapy. Expert Opin Ther Targets 2005;9:383-94
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G, Bianco C, Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene 1994;9:291-8
   PubMed Web of Science ®Google Scholar
• De Luca A, Casamassimi A, Selvam MP, EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. Int J Cancer 1999;80:589-94
   Google Scholar
• De Luca A, Arra C, D'Antonio A, Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene 2000;19:5863-71
   PubMed Web of Science ®Google Scholar
• Casamassimi A, De Luca A, Agrawal S, EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. Ann Oncol 2000;11:319-25
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Maiello MR, CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. Int J Oncol 2004;25:1013-20
   PubMed Web of Science ®Google Scholar
• Normanno N, Tortora G, De Luca A, Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. Oncol Rep 1999;6:1105-9
   Google Scholar
• De Luca A, Selvam MP, Sandomenico C, Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. Int J Cancer 1997;73:277-82
   Google Scholar
• Deckert PM. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr Drug Targets 2009;10(2):158-75
   Google Scholar
• Biogen-Idec. Cripto binding molecules. US0008906; 2010
   Google Scholar
• Almagro JC, Fransson J. Humanization of antibodies. Front Biosci 2008;13:1619-33
   PubMed Web of Science ®Google Scholar
• Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107
   PubMed Web of Science ®Google Scholar
• Xing PX, Hu XF, Pietersz GA, Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res 2004;64:4018-23
   PubMed Web of Science ®Google Scholar
• McKenzie IFC, Xing PX, Hu XF. Antibodies against cancer. US0119514; 2010
   Google Scholar
• Hu XF, Li J, Yang E, Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br J Cancer 2007;96:918-27
   PubMed Web of Science ®Google Scholar
• Gray PC, Shani G, Kelber JA, Vale W. Compositions and methods for the inhibition of Cipto/GRP78 complex formation and signaling. US0135904; 2010
   Google Scholar
• Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 2005;35:373-81
   PubMed Web of Science ®Google Scholar
• Davidson DJ, Haskell C, Majest S, Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res 2005;65:4663-72
   PubMed Web of Science ®Google Scholar
• Kelber JA, Panopoulos AD, Shani G, Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 2009;28:2324-36
   PubMed Web of Science ®Google Scholar
• Bianco C, Salomon DS. Human Cripto-1 as a target for a cancer vaccine: WO2008040759. Expert Opin Ther Pat 2009;19:141-4
   PubMed Web of Science ®Google Scholar
• Pharmexa. Methods of down-regulation of Cripto. WO2008040759; 2008
   Google Scholar
• Glaxosmithkline. Vaccines. US2008249013; 2008
   Google Scholar
• Parisi S, D'Andrea D, Lago CT, Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells. J Cell Biol 2003;163:303-14
   PubMed Web of Science ®Google Scholar
• Parish CL, Parisi S, Persico MG, Cripto as a target for improving embryonic stem cell-based therapy in Parkinson's disease. Stem Cells 2005;23:471-6
   PubMedGoogle Scholar
• Sonntag KC, Simantov R, Bjorklund L, Context-dependent neuronal differentiation and germ layer induction of Smad4-/- and Cripto-/- embryonic stem cells. Mol Cell Neurosci 2005;28:417-29
   Google Scholar
• Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci 2005;28:86-92
   PubMed Web of Science ®Google Scholar
• Kriks S, Studer L. Protocols for generating ES cell-derived dopamine neurons. Adv Exp Med Biol 2009;651:101-11
   PubMed Web of Science ®Google Scholar
• Lonardo E, Parish CL, Ponticelli S, A small synthetic Cripto blocking Peptide improves neural induction, dopaminergic differentiation, and functional integration of mouse embryonic stem cells in a rat model of Parkinson's disease. Stem Cells 2010;28:1326-37
   Google Scholar
• Stephens EB, Jackson M, Cui L, Early dysregulation of Cripto-1 and immunomodulatory genes in the cerebral cortex in a macaque model of neuroAIDS. Neurosci Lett 2006;410:94-9
   PubMed Web of Science ®Google Scholar
• Salomon DS, Berman N. Use of Cripto-1 as a biomarker for neurodegenerative disease and method to inhibit progression thereof. US2007122813; 2007
   Google Scholar
• Tedesco FS, Dellavalle A, Diaz-Manera J, Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest 2010;120:11-19
   PubMed Web of Science ®Google Scholar
• Minchiotti G, Carmeliet P. Means and methods for the stimulation of skeletal muscle regeneration. WO2008028888; 2008
   Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E, Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-15
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID, Identification of human brain tumour initiating cells. Nature 2004;432:396-401
   PubMed Web of Science ®Google Scholar
• Watanabe K, Meyer MJ, Strizzi L, Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. Stem Cells 2010;28:1303-14
   PubMed Web of Science ®Google Scholar
• Cocciadiferro L, Miceli V, Kang KS, Profiling cancer stem cells in androgen-responsive and refractory human prostate tumor cell lines. Ann NY Acad Sci 2009;1155:257-62
   PubMed Web of Science ®Google Scholar
• Strizzi L, Abbott DE, Salomon DS, Hendrix MJ. Potential for Cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle 2008;7:1931-5
   PubMed Web of Science ®Google Scholar